| Species |
Human |
| Protein Construction |
Complement C1s (Glu16-Asp688)
Accession # P09871 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Complement C1s, His, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiC1S Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
75.98 kDa |
| Apparent Molecular Weight |
Due to enzyme lysis glycosylation, the protein migrates to 55-60 kDa (light chain), 32-35 kDa (heavy chain) and 76-96 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). |
| Synonyms |
EDSPD2; C1 esterase;Complement Component C1s |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
